Sandipkumar S. Kapadia

Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.

Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The private company is based in Bristol, UK.

Founded in 2015, Intercept Pharma UK & Ireland Ltd. is a pharmaceutical wholesaler. Part of Intercept Pharmaceuticals, Inc., the private company is based in Bristol, UK.

Part of Intercept Pharmaceuticals, Inc., Intercept Pharma Deutschland GmbH is a German company focused on building a healthier tomorrow for patients with progressive non-viral liver diseases. The private company is based in Munich, Germany. The CEOs are Rocco Venezia, Michael Gemellaro, Willem Wouter Van Weperen. The company was founded in 2015.

Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz.

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.

VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland.